Efficacy of recombinant human endostatin (Endostar) combined with chemotherapy for malignant pleural effusion in non-small cell lung cancer patients
10.3969/j.issn.1000-8179.20141512
- VernacularTitle:重组人血管内皮抑制素联合化疗治疗非小细胞肺癌恶性胸腔积液的疗效观察
- Author:
Jie XU
;
Daliang QI
;
Xubin LI
;
Ruixia WANG
- Publication Type:Journal Article
- Keywords:
malignant pleural effusion;
recombinant human endostatin;
nedaplatin;
non-small cell lung cancer
- From:
Chinese Journal of Clinical Oncology
2014;(24):1573-1576
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To study the efficacy and safety of the intrapleural injection of nedaplatin combined with recombinant hu-man endostatin (Endostar) in the treatment of malignant pleural effusion in non-small cell lung cancer (NSCLC) patients. Methods:Seventy patients diagnosed with NSCLC with malignant pleural effusion were treated by intrapleural injection. The subjects were divid-ed into two groups, as follows: 35 cases were injected with nedaplatin and Endostar (the treatment group) and 35 cases were injected with nedaplatin only (the control group). One month after the treatment, the clinical efficacy and toxicity were evaluated. The clinical ef-ficacy, quality of life, and toxic reaction were compared between the two groups. Results: The short-term clinical efficacy rate of the treatment group was 74.28%, whereas that of the control group was 48.57%, and the difference between the two groups was significant (P<0.05). Adverse effects such as nausea vomiting and leukopenia, occurred in both groups, but no significant differences were found between the two groups (P>0.05). Conclusion: The efficacy of the intrapleural injection of recombinant human endostatin combined with nedaplatin is superior to that of cisplatin alone in the treatment of malignant pleural effusion, without increasing chemotherapeutic toxicity.
